Under construction – not a live service
Sign in
Not yet taking people in SpainPhase 3

Eloralintide Study for Weight, Diabetes and Heart Risk in Adults

Tests eloralintide against placebo in adults with obesity, diabetes and heart risk.

Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

Key facts

Where
A Coruña, Alzira, Castilleja De La Cuesta, Ferrol, Granada, Lugo, Madrid, Majadahonda, Palma, Pozuelo de Alarcón, Santander, Sevilla, and Valencia, SpainSee the 14 sites
Phase
Phase 3

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 45 to 64 with type 2 diabetes, overweight or obesity, and a higher risk of heart and blood vessel problems.

Age
45 to 64 years
Sex
All sexes can join.
Disease stage
Type 2 diabetes with HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol), BMI ≥ 25.0 kg/m2, and an increased risk of cardiovascular events.
Earlier treatment
On stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening. At least one self-reported unsuccessful dietary effort to lose weight.
Biomarker or test result
HbA1c between ≥ 6.5% (48 mmol/mol) and ≤ 9.5% (80 mmol/mol) at screening.

Main reasons for not taking part

  • Type 1 diabetes
  • Prior or planned surgery, endoscopic procedure or device-based therapy for obesity (some exceptions apply)
  • New York Heart Association Functional Classification IV congestive heart failure
  • Within 60 days before screening: heart attack, stroke, hospitalization for heart failure, or artery revascularization
  • Sulfonylurea combined with insulin within 90 days before screening

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 45 and 64 years old?

Source: NCT07900633, who can take part

Where in Spain

  • Complexo Hospitalario Universitario A CoruñaA Coruña, SpainNot yet recruiting
  • Hospital Universitario de La RiberaAlzira, SpainNot yet recruiting
  • Hospital Nisa Sevilla AljarafeCastilleja De La Cuesta, SpainNot yet recruiting
  • Area Sanitaria De FerrolFerrol, SpainNot yet recruiting
  • Hospital Vithas La SaludGranada, SpainNot yet recruiting
  • Hospital Polusa S.A.Lugo, SpainNot yet recruiting
  • Hospital Universitario La PazMadrid, SpainNot yet recruiting
  • Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainNot yet recruiting
  • University Hospital Son EspasesPalma, SpainNot yet recruiting
  • Hospital Universitario Quironsalud MadridPozuelo de Alarcón, SpainNot yet recruiting
  • Hospital Universitario Marqués de ValdecillaSantander, SpainNot yet recruiting
  • Nuevas Tecnologias En Diabetes Y En Endocrinologia S.L. ProfesionalSevilla, SpainNot yet recruiting
  • University Hospital Virgen Del Rocio S.L.Sevilla, SpainNot yet recruiting
  • Hospital Clinico Universitario de ValenciaValencia, SpainNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT07900633EU 2026-525919-14-00
Record updated
3 November 2026
Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.Read full original descriptionShow less

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once-Weekly Eloralintide in Adult Participants With Obesity or Overweight, Type 2 Diabetes, and Increased CV Risk

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.

Inclusion: Have type 2 diabetes; Have a HbA1c value between ≥ 6.5% and ≤ 9.5% at screening; Are on stable treatment with an unchanged dose of at least 1 and no more than 4 antihyperglycemic therapies for at least 90 days before screening; Have an increased risk of cardiovascular events; Have a BMI ≥ 25.0 kg/m2 at screening; Have a stable body weight (<5% body weight change) for 90 days prior to screening; Have a history of at least one self-reported unsuccessful dietary effort to reduce body weight.

Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 60 days prior to screening:; acute myocardial infarction; stroke; hospitalization for congestive heart failure, or; coronary, peripheral, or carotid artery revascularization procedure; Have received treatment combining sulfonylurea and insulin within 90 days prior to screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification IV congestive heart failure.

ClinicalTrials.gov NCT07900633 · EU CTIS 2026-525919-14-00